Halozyme Therapeutics reported $1.75M in Interest Expense on Debt for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Alnylam Pharmaceuticals ALNY:US $ 33.42M 901K
Amarin AMRN:US $ 0.03M 0.02M
Amgen AMGN:US $ 281M 4M
Arena Pharmaceuticals ARNA:US $ 1.05M 0.02M
Baxter International BAX:US $ 37M 0M
Cytokinetics CYTK:US $ 4.07M 0.08M
Eli Lilly And LLY:US $ 86.9M 0.9M
Esperion Therapeutics ESPR:US $ 11.14M 3.02M
Halozyme Therapeutics HALO:US $ 1.75M 0.21M
Immunogen IMGN:US $ 3.58M 1.09M
Intercept Pharmaceuticals ICPT:US $ 12.59M 0.17M
JAZZ PHA JAZZ:US $ 69.82M 41.24M
Mannkind MNKD:US $ 3.18M 3.27M
Nektar Therapeutics NKTR:US $ 13.09M 0.21M
Peregrine Pharmaceuticals PPHM:US 703K 461K
Pfizer PFE:US $ 316M 20M
Rigel Pharmaceuticals RIGL:US $ 1.76M 1.27M
United Therapeutics UTHR:US $ 4.7M 0.1M